WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Trump's 'Truth Social' applied for HColombia rolls out new incentives to cut electricity consumption as dry weather persistsAlcaraz is cautious ahead of Madrid Open. The Spaniard is not 100% sure he will playFormer Green Bay player Kayla Karius leaves South Dakota to return to her alma mater as coachTensions simmer near a shoal both China and the Philippines claim — Radio Free AsiaCyberattacks are on the rise, and that includes small businesses. Here's what to knowHousing crisis laid bare as couple turn disused bus stop into a temporary homeMinnesota State Sen. Nicole Mitchell charged with firstThese apps allow workers to get paid between paychecks. Experts say there are steep costsTeresa Giudice, 51, of RHONJ poses with her mini
2.7794s , 5260.3984375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Planet Panorama news portal